Concentrum Wealth Management Increases Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Concentrum Wealth Management lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,766 shares of the biopharmaceutical company’s stock after acquiring an additional 413 shares during the quarter. Concentrum Wealth Management’s holdings in Gilead Sciences were worth $548,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Los Angeles Capital Management LLC lifted its stake in Gilead Sciences by 53.5% in the 4th quarter. Los Angeles Capital Management LLC now owns 1,437,031 shares of the biopharmaceutical company’s stock valued at $116,414,000 after buying an additional 501,105 shares in the last quarter. Natixis Advisors L.P. lifted its stake in Gilead Sciences by 15.1% in the 4th quarter. Natixis Advisors L.P. now owns 279,620 shares of the biopharmaceutical company’s stock valued at $22,652,000 after buying an additional 36,711 shares in the last quarter. Commonwealth Equity Services LLC lifted its stake in Gilead Sciences by 12.9% in the 4th quarter. Commonwealth Equity Services LLC now owns 372,452 shares of the biopharmaceutical company’s stock valued at $30,172,000 after buying an additional 42,554 shares in the last quarter. Robertson Stephens Wealth Management LLC lifted its stake in Gilead Sciences by 32.4% in the 4th quarter. Robertson Stephens Wealth Management LLC now owns 5,349 shares of the biopharmaceutical company’s stock valued at $433,000 after buying an additional 1,310 shares in the last quarter. Finally, McIlrath & Eck LLC lifted its stake in Gilead Sciences by 67.2% in the 4th quarter. McIlrath & Eck LLC now owns 550 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 221 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

GILD has been the topic of a number of recent research reports. TD Cowen reduced their target price on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Friday, April 26th. Royal Bank of Canada cut their price target on Gilead Sciences from $76.00 to $74.00 and set a “sector perform” rating for the company in a report on Friday, April 26th. HSBC upgraded Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price target for the company in a report on Wednesday, April 24th. Truist Financial downgraded Gilead Sciences from a “buy” rating to a “hold” rating and cut their price target for the company from $91.00 to $82.00 in a report on Thursday, February 22nd. Finally, Mizuho cut their price target on Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a report on Thursday, February 22nd. Eleven investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Gilead Sciences currently has an average rating of “Hold” and an average price target of $83.69.

Insider Buying and Selling

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the transaction, the insider now directly owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 0.16% of the stock is owned by corporate insiders.

Gilead Sciences Trading Down 0.3 %

Shares of GILD stock traded down $0.22 on Thursday, reaching $65.29. 2,740,160 shares of the stock were exchanged, compared to its average volume of 7,421,412. The stock has a market cap of $81.29 billion, a P/E ratio of 180.94, a price-to-earnings-growth ratio of 1.31 and a beta of 0.22. The company has a quick ratio of 0.72, a current ratio of 0.98 and a debt-to-equity ratio of 1.08. The firm has a 50 day moving average of $70.87 and a two-hundred day moving average of $76.01. Gilead Sciences, Inc. has a 1-year low of $64.63 and a 1-year high of $87.86.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The business had revenue of $6.69 billion during the quarter, compared to the consensus estimate of $6.36 billion. During the same period in the prior year, the firm posted $1.37 EPS. The business’s revenue for the quarter was up 5.3% on a year-over-year basis. On average, research analysts anticipate that Gilead Sciences, Inc. will post 3.74 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be given a dividend of $0.77 per share. The ex-dividend date is Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a yield of 4.72%. Gilead Sciences’s dividend payout ratio (DPR) is 855.56%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.